
English and Italian national health systems are predominantly funded by general taxation and treat patients primarily free at the point of delivery. Both healthcare systems are facing increasing financial pressures given population ageing, the rise in chronic and non-communicable diseases, and fiscal restraint. In recent years, pressures on public healthcare have revived debate around the role of the private sector, but discussion is mired in a lack of conceptual clarity. We seek to bring greater analytical order by distinguishing seven distinct 'trajectories of privatisation', each reflecting different modes and logics of interaction between public and private actors. We examine two similar health systems - England and Italy - highlight their similarities and differences regarding emerging and established trajectories. There is less evidence of 'hard privatisation', seen as the private share of overall spending; however, both countries are experiencing greater use of on-demand staff and financialisation. In both systems subtler privatisation dynamics (public-private partnerships, managerialism, and entrepreneurialism) are redefining and blurring the boundaries between public and private provision. Public perceptions of perceived privatisation are shaped by direct, tangible experiences of care and out-of-pocket spending. Some privatisation dynamics are mainly driven by behaviour of patients, professionals, and investors rather than by policies.
Moral hazard is built into the structure of private equity investments, which incentivises debt-based extraction rather than value-adding investment. To craft effective regulation of private equity’s participation in healthcare, and to cut through the industry’s talking points, we must reframe and acknowledge private equity ‘investment’ as ‘extraction’. In the U.S. healthcare system, this debt-based extraction has produced higher risks of bankruptcy and financial distress and associated facility closures, cost-cutting that affects patient safety and care, rising healthcare costs, inefficient use of taxpayer dollars, erosion of clinician autonomy, and increased consolidation. Policies that address extractive behaviours are the most targeted and efficient means of safeguarding patient care and may discourage the worst actors from acquiring healthcare providers. As private equity invests in health systems beyond the U.S. where regulatory regimes differ, the fundamentals of its extractive business model remain the same. Regulations must be calibrated to country specifics, but they should address the debt-based extraction built into the very structure of private equity investments. As policy debates continue, it is worth asking why we need private equity’s extractive business model in healthcare in the first place.
The No Surprises Act (NSA), signed into law by President Trump over five years ago, marked a significant federal intervention aimed at shielding millions of consumers with private health coverage from unexpected out-of-network medical bills. While the Act is lauded for successfully protecting consumers, its implementation has been plagued by aggressive litigation, with provider-led lawsuits challenging the Act itself as well as every rule issued to implement the protections and countless other lawsuits challenging actions (or inactions) by providers, insurers, and independent dispute resolution (IDR) entities. This litigation has profoundly impacted the Act’s cost-saving objectives by eroding its payment methodology and fostering extensive use of the IDR process. This paper chronicles the litigation timeline from the passage of the NSA through April 2026 and its impacts on the implementation, detailing the challenges to the regulatory framework and how adversarial legalism shaped the NSA’s trajectory. The paper concludes by offering policy options for Congress, federal agencies, states, and stakeholders to reduce costs and IDR volume to better align with the intent of the NSA.
This study presents the first comprehensive global mapping and inductive classification of digital welfare platforms. Drawing on an original dataset of 285 cases spanning diverse institutional and geographical contexts, it identifies five core functional types: service delivery, information repository, search engine, value co-creation, and community-building. Using a multidimensional descriptive approach and a structured decision-tree model, the analysis reveals significant divergence in governance arrangements, user orientation, monetisation strategies, and business models. While digital platforms are often promoted as tools for enhancing accessibility and efficiency, the findings expose critical systemic voids - particularly in public sector involvement, youth-focused provision, and accountability mechanisms. The study highlights the fragmented and commercially skewed nature of emerging digital welfare infrastructures, raising pressing concerns about equity, inclusion, and the normative trajectories shaping welfare governance in the platform era.
China’s ‘Four Frees and One Care’ policy provides people living with HIV (PLHIV) with free antiretroviral drugs (ARVs), while the recent inclusion of new ARVs in medical insurance policy has created policy overlap. Guided by the Institutional Analysis and Development (IAD) framework, this qualitative study used semi-structured interviews with 42 Centers for Disease Control and Prevention (CDC) and medical staff across China to examine institutional interactions and tensions in implementing the ‘Four Frees and One Care’ policy under policy overlap. The findings indicate that CDC and medical institutions exhibit divergent perceptions regarding the scope of beneficiaries for free ARVs, the allocation of responsibilities during implementation, and preferences in ARVs recommendations. CDC staff place greater emphasis on expanding antiretroviral therapy (ART) coverage to achieve public health goals for HIV control at the population level, whereas medical institutions focus more on individual treatment outcomes and the healthcare service performance. This divergence results in CDC favouring the free ARVs policy in practice, while medical institutions are more inclined toward ARVs accessed through medical insurance. Such tensions not only affect the coordination of policy implementation but may also have potential adverse impacts on PLHIV access to ART services, ART adherence, and public health outcomes.